Learned Helplessness As a Potential Transdiagnostic Therapeutic Mechanism of Classic Psychedelics
Praachi Tiwari, Andrea P Berghella, Ceyda Sayalı, Manoj K. Doss, Frederick S. Barrett, David B. Yaden
Psychedelic Medicine June 1, 2023 DOI: 10.1089/psymed.2023.0010 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Keywords | Learned helplessness Mechanism biology Psychotherapist Cognitive psychology Clinical psychology Epistemology |
| Citations | 9 |
| Key points | Proposes that reversal of and resilience against learned helplessness may be a key therapeutic mechanism of classic psychedelics, and that the learned helplessness paradigm can serve as a model for investigating these effects. |
Abstract
Background: Emerging literature suggests that classic psychedelics may have efficacy in treating mood and substance use disorders in humans. This has raised questions regarding the primary therapeutic mechanism of these compounds. Here, we hypothesize that the reversal of and resilience against learned helplessness may be an important driver of the therapeutic mechanisms of classic psychedelics. Furthermore, we argue that the learned helplessness paradigm can provide a robust model to investigate the behavioral and mechanistic effects of classic psychedelics in both clinical and preclinical experiments. Opinion: We highlight the learned helplessness model and its potential utility in the psychedelic sphere for several reasons. First, learned helplessness is a robust phenomenon observed across multiple mammalian species including humans, and has been well described in terms of its neurobiology, behavioral effects, and clinical implications; current efforts in psychedelic research and theories of psychedelic mechanisms have yet to achieve this level of integration. Interestingly, there is substantial overlap in the neural circuits governing resilience against learned helplessness and psychedelic actions-such as those involving the dorsal raphe nucleus. Furthermore, our hypothesis that classic psychedelics can reverse helplessness behavior fits with much of the current preclinical data, which has shown that psychedelics improve performance in behavioral despair tasks in rodents. Here we make the case for bringing attention to these congruencies in an effort to advance toward mechanistic, behavioral, and transdiagnostic insights into the therapeutic effects of classic psychedelics, with the potential for learned helplessness to help explain some positive effects across levels of analysis.
Citations in the library
Cited by 7
- Survival, Attachment, and Healing: An Evolutionary Lens on Interventions for Trauma-Related Dissociation Psychology Research and Behavior Management June 1, 2024
- Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach. Frontiers in Psychiatry 2025
- Resetting the Hippocampal Buffer: A Neurocognitive Account of Psychedelic Therapy for Anxiety-Related Psychopathology May 26, 2024
- N,N-dimethyltryptamine elicits antidepressant and anxiolytic effects in helpless mice: a comparative study with S-ketamine. Neuropharmacology July 1, 2026
- Psychodynamic Perspectives on Psychedelic States and Treatment Contexts: A Conceptual and Clinical Introduction. Psychodynamic psychiatry June 1, 2026
and 2 more in the library
Cites 62
- mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists Science August 19, 2010
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
and 57 more in the library